A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li (), Qi Zhu () and Lai-ping Zhong ()
Additional contact information
Wu-tong Ju: Shanghai Jiao Tong University School of Medicine
Rong-hui Xia: Shanghai Jiao Tong University School of Medicine
Dong-wang Zhu: Shanghai Jiao Tong University School of Medicine
Sheng-jin Dou: Shanghai Jiao Tong University School of Medicine
Guo-pei Zhu: Shanghai Jiao Tong University School of Medicine
Min-jun Dong: Shanghai Jiao Tong University School of Medicine
Li-zhen Wang: Shanghai Jiao Tong University School of Medicine
Qi Sun: Shanghai Jiao Tong University School of Medicine
Tong-chao Zhao: Shanghai Jiao Tong University School of Medicine
Zhi-hang Zhou: Shanghai Jiao Tong University School of Medicine
Si-yuan Liang: Shanghai Jiao Tong University School of Medicine
Ying-ying Huang: Shanghai Jiao Tong University School of Medicine
Yong Tang: Shanghai Jiao Tong University School of Medicine
Si-cheng Wu: Shanghai Jiao Tong University School of Medicine
Jing Xia: The Medical Department, 3D Medicines Inc.
Shi-qing Chen: The Medical Department, 3D Medicines Inc.
Yue-zong Bai: The Medical Department, 3D Medicines Inc.
Jiang Li: Shanghai Jiao Tong University School of Medicine
Qi Zhu: Shanghai Jiao Tong University School of Medicine
Lai-ping Zhong: Shanghai Jiao Tong University School of Medicine

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma (OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable OSCC receive three cycles of camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily) before surgery. The primary endpoints are safety and major pathological response (MPR, defined as ≤10% residual viable tumour cells). Secondary endpoints include 2-year survival rate and local recurrence rate (not reported due to inadequate follow-up). Exploratory endpoints are the relationships between PD-L1 combined positive score (CPS, defined as the number of PD-L1-stained cells divided by the total number of viable tumour cells, multiplied by 100) and other immunological and genomic biomarkers and response. Neoadjuvant treatment is well-tolerated, and the MPR rate is 40% (8/20), meeting the primary endpoint. All five patients with CPS ˃10 achieve MPR. Post-hoc analysis show 18-month locoregional recurrence and survival rates of 10.5% (95% CI: 0%–24.3%) and 95% (95% CI: 85.4%–100.0%), respectively. Patients achieving MPR show more CD4+ T-cell infiltration than those without MPR (P = 0.02), and decreased CD31 and ɑ-SMA expression levels are observed after neoadjuvant therapy. In conclusion, neoadjuvant camrelizumab and apatinib is safe and yields a promising MPR rate for OSCC.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33080-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33080-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33080-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().